Xtandi (enzalutamide) Disease area(s): Oncology Manufacturer(s): Astellas/Pfizer 2024 Sales (USD): $7.94 billion Why it sold so well: In 2024, Astellas Pharmas Xtandi, co-marketed with Pfizer, posted strong sales growth, with revenues reaching 703.1 billion ($4.64 billion) for the first nine months (April 1, 2024 to December 31, 2024), marking a 25.6% increase compared to the same period in the previous year
Instalaciones y tecnologa de ltima generacin Creemos en construir asociaciones duraderas con nuestros pacientes, guindolos hacia vidas ms saludables y plenas
Maximize nutrient density: Every calorie counts since volume is limited
An improper diet leads to weight gain, which increases mechanical pressure on the knee joints
And the results were similarly stunning
Taking appropriate supplements alongside tirzepatide and managing inflammation can help reduce discomfort